Humanoid, a London-based robotics company founded in May 2024 by Artem Sokolov, has secured $152 million in fresh capital at a $1.35 billion valuation. The funding round expands the company’s resource base as it prepares to move from pre-order activity to commercial availability, with a beta version expected in the fourth quarter of 2026.
Investment round and backers
The financing round was led by Prime Movers Lab and included participation from Bosch, Schaeffler, Fubon Financial Holding Venture Capital and Aglaé Ventures. The injection of $152 million brings Humanoid’s total disclosed funding since 2024 to $270 million, marking a significant accumulation of capital in a relatively short period following the company’s launch earlier this year.
Investors participating in the round span a mix of venture and corporate backers. The presence of these participants will provide the company with a widened capital base as it scales towards commercial production and the expected beta release in late 2026.
Pre-orders and commercial readiness
Prior to the shipment of commercial units, Humanoid has recorded 34,000 pre-orders valued at $2.4 billion. These pre-orders were placed before commercial units were shipped, indicating substantial market interest ahead of wide-scale delivery. The level of advance demand stands considerably higher than the funding round itself and highlights the scale of confirmed buyer intent the company is carrying into the development and production phases.
The company has set a timeline for a beta version in the fourth quarter of 2026. That schedule frames the next phase of Humanoid’s development, moving from pre-orders and product refinement to initial commercial validation. The forthcoming beta will be a key milestone in determining how the company converts pre-order commitments into delivered units.
Founding and pace of fundraising
Humanoid was founded in London in May 2024 by Artem Sokolov. Since that founding date the company has amassed $270 million in total funding. The latest round, contributing $152 million, represents a substantial portion of that total and pushes the company past the unicorn threshold implied by its $1.35 billion valuation.
The speed and scale of capital accumulation, combined with the volume and value of pre-orders, set a demanding agenda for the company as it works towards product completion and market entry. The timeline toward a beta release in late 2026 will require continued coordination of engineering, production planning and capital deployment.
Outlook
With the new funding and a significant backlog of pre-orders, Humanoid moves into the next phase of its trajectory—transitioning from product development to commercial delivery. The alignment of investor support, pre-order demand and an articulated beta timeline provides the company with measurable milestones to manage over the coming months. How effectively it translates pre-orders into shipped units and how the beta phase informs broader commercial roll-out will shape the company’s immediate prospects.
As Humanoid progresses toward the fourth-quarter 2026 beta, the market will be watching how the company balances technical development, manufacturing readiness and customer fulfilment against the expectations set by its valuation and pre-order commitments.
As this situation develops, it will be important to monitor the ongoing implications for the local community and the wider region. Authorities and relevant stakeholders are expected to provide further updates in due course, ensuring that the public remains informed of any material changes. The broader context of these events highlights the continuing need for clear communication, robust planning, and effective coordination among all parties involved. Readers are advised to consult official channels for the most current and accurate information as the timeline progresses.
